These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 1674950)

  • 1. Effects of nifedipine on psychosis and tardive dyskinesia in schizophrenic patients.
    Stedman TJ; Whiteford HA; Eyles D; Welham JL; Pond SM
    J Clin Psychopharmacol; 1991 Feb; 11(1):43-7. PubMed ID: 1674950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients.
    Reiter S; Adler L; Angrist B; Peselow E; Rotrosen J
    J Clin Psychiatry; 1989 Jan; 50(1):26-7. PubMed ID: 2562952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stable remission of tardive dyskinesia by L-dopa.
    Ludatscher JI
    J Clin Psychopharmacol; 1989 Feb; 9(1):39-41. PubMed ID: 2565346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM; Yu SC; Lin CC
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
    Silver H; Geraisy N; Schwartz M
    J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buspirone in the treatment of tardive dyskinesia.
    Moss LE; Neppe VM; Drevets WC
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study.
    Lerner V; Kaptsan A; Miodownik C; Kotler M
    Clin Neuropharmacol; 1999; 22(4):241-3. PubMed ID: 10442256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical trial of nifedipine in schizophrenia and tardive dyskinesia.
    Suddath RL; Straw GM; Freed WJ; Bigelow LB; Kirch DG; Wyatt RJ
    Pharmacol Biochem Behav; 1991 Jul; 39(3):743-5. PubMed ID: 1686106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative treatment of tardive dyskinesia with combination of amantadine-neuroleptic administration.
    Allen RM
    Biol Psychiatry; 1982 Jun; 17(6):719-27. PubMed ID: 6179548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
    Chouinard G; Safadi G; Beauclair L
    J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
    Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
    Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of akathisia in patients receiving stable doses of clozapine.
    Chengappa KN; Shelton MD; Baker RW; Schooler NR; Baird J; Delaney J
    J Clin Psychiatry; 1994 Apr; 55(4):142-5. PubMed ID: 7915271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levetiracetam in tardive dyskinesia.
    Meco G; Fabrizio E; Epifanio A; Morgante F; Valente M; Vanacore N; Di Rosa AE; Morgante L
    Clin Neuropharmacol; 2006; 29(5):265-8. PubMed ID: 16960471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmaco-clinical correlations during fluoxetine administration in patients with depressive schizophrenia treated with haloperidol decanoate].
    Viala A; Aymard N; Leyris A; Caroli F
    Therapie; 1996; 51(1):19-25. PubMed ID: 8762216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.